Literature DB >> 23121275

Evidence-based guidelines for pediatric clinical trials: focus on StaR Child Health.

Mario R Sampson1, Daniel K Benjamin, Michael Cohen-Wolkowiez.   

Abstract

Clinical trials in children are challenging and filled with important ethical considerations that differ from adults. Given difficulties associated with pediatric clinical trials, off-label prescribing is a common practice in pediatrics, which can lead to adverse safety events and efficacy failures. To overcome these consequences, in the past 15 years, legislation in the USA and Europe has provided incentives to industry and increased government funding to conduct pediatric trials. Pediatric trial networks have also been formed to decrease the knowledge gap. However, challenges to performing pediatric trials and lack of standardization and guidelines regarding studies in children still exist. Standards for Research (StaR) in Child Health, begun in 2009, aims to improve the design, conduct and reporting of pediatric trials. This organization uses a consensus guideline approach involving academic, government and industry stakeholders to identify and disseminate best practices for pediatric trials. Six out of 11 planned standards are currently published.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23121275      PMCID: PMC3566240          DOI: 10.1586/ecp.12.52

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  19 in total

1.  Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project.

Authors: 
Journal:  Qual Saf Health Care       Date:  2003-02

2.  Fatal circulatory collapse in premature infants receiving chloramphenicol.

Authors:  L E BURNS; J E HODGMAN; A B CASS
Journal:  N Engl J Med       Date:  1959-12-24       Impact factor: 91.245

3.  A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens.

Authors:  D H ANDERSEN; W A BLANC; D N CROZIER; W A SILVERMAN
Journal:  Pediatrics       Date:  1956-10       Impact factor: 7.124

Review 4.  Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety.

Authors:  Laura Cuzzolin; Alessandra Atzei; Vassilios Fanos
Journal:  Expert Opin Drug Saf       Date:  2006-09       Impact factor: 4.250

Review 5.  Ethical dilemmas in medical innovation and research: distinguishing experimentation from practice.

Authors:  N Fost
Journal:  Semin Perinatol       Date:  1998-06       Impact factor: 3.300

6.  Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study.

Authors:  S Turner; A J Nunn; K Fielding; I Choonara
Journal:  Acta Paediatr       Date:  1999-09       Impact factor: 2.299

Review 7.  Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature.

Authors:  L Lindell-Osuagwu; M J Korhonen; S Saano; M Helin-Tanninen; T Naaranlahti; H Kokki
Journal:  J Clin Pharm Ther       Date:  2009-06       Impact factor: 2.512

Review 8.  Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group.

Authors:  Maura O'Leary; Mark Krailo; James R Anderson; Gregory H Reaman
Journal:  Semin Oncol       Date:  2008-10       Impact factor: 4.929

9.  Open clinical trial data for all? A view from regulators.

Authors:  Hans-Georg Eichler; Eric Abadie; Alasdair Breckenridge; Hubert Leufkens; Guido Rasi
Journal:  PLoS Med       Date:  2012-04-10       Impact factor: 11.069

10.  Children are not just small adults: the urgent need for high-quality trial evidence in children.

Authors:  Terry P Klassen; Lisa Hartling; Jonathan C Craig; Martin Offringa
Journal:  PLoS Med       Date:  2008-08-12       Impact factor: 11.069

View more
  5 in total

Review 1.  2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.

Authors:  Craig A Sable; D Dunbar Ivy; Robert H Beekman; Helene D Clayton-Jeter; Kathy J Jenkins; William T Mahle; William R Morrow; Mary Dianne Murphy; Robert M Nelson; Geoffrey L Rosenthal; Norman Stockbridge; David L Wessel
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-07

2.  2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.

Authors:  Craig A Sable; D Dunbar Ivy; Robert H Beekman; Helene D Clayton-Jeter; Kathy J Jenkins; William T Mahle; William R Morrow; Mary Dianne Murphy; Robert M Nelson; Geoffrey L Rosenthal; Norman Stockbridge; David L Wessel
Journal:  J Am Coll Cardiol       Date:  2017-06-29       Impact factor: 24.094

3.  Inclusion of women susceptible to and becoming pregnant in preregistration clinical trials in low- and middle-income countries: A proposal for neglected tropical diseases.

Authors:  Monique Couderc-Pétry; Elisabeth Eléfant; Monique Wasunna; Alwyn Mwinga; Nilima A Kshirsagar; Nathalie Strub-Wourgaft
Journal:  PLoS Negl Trop Dis       Date:  2020-06-11

4.  Recommendations and evidence for reporting items in pediatric clinical trial protocols and reports: two systematic reviews.

Authors:  April V P Clyburne-Sherin; Pravheen Thurairajah; Mufiza Z Kapadia; Margaret Sampson; Winnie W Y Chan; Martin Offringa
Journal:  Trials       Date:  2015-09-18       Impact factor: 2.279

Review 5.  Drug Safety in Translational Paediatric Research: Practical Points to Consider for Paediatric Safety Profiling and Protocol Development: A Scoping Review.

Authors:  Beate Aurich; Evelyne Jacqz-Aigrain
Journal:  Pharmaceutics       Date:  2021-05-11       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.